ZS Pharma Announces Publication Of Results From Phase 3 Study Of ZS-9 In Patients With Hyperkalemia In The New England Journal Of Medicine

ZS Pharma

, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the publication of previously unreleased detailed results from the ZS003 study in the New England Journal of Medicine (NEJM). ZS003 was a Phase 3, 753 patient, multicenter, randomized, double-blind, placebo-controlled trial that assessed the safety and efficacy of ZS-9 (sodium zirconium cyclosilicate) in treating patients with hyperkalemia, a life threatening condition characterized by abnormally high concentrations of potassium in the blood (serum K+ ≥5.1 mEq/L). "We were pleased with the ability of ZS-9 to lower serum potassium in hyperkalemic patients as hyperkalemia is associated with increased mortality in patients with heart failure, chronic kidney disease and diabetes," said the article's lead author, David K. Packham, MBBS(Hons), FRCP, FRACP, MD, from the Royal Melbourne Hospital in Australia. "If ZS-9 receives regulatory approval, I believe it could be a useful tool in the treatment and management of hyperkalemia." The peer-reviewed study, "Sodium Zirconium Cyclosilicate (ZS-9) in Hyperkalemia," will also appear in the journal's print issue.